An RNA sequencing study led by Per Uhlén from Karolinska Institutet identifies the gene COX7B to be associated with cancer cell resistance to platinum-based chemotherapy, such as cisplatin. The results also demonstrate that the membrane-associated protein CD63 may be used as a surrogate marker for platinum resistance.
Knock-down of COX7B in cancer cells decreased the sensitivity to cisplatin, whereas overexpression recovered the sensitivity. In addition, low COX7B levels correlated with higher mortality rates in patients with various types of cancer and were significantly associated with poor response to chemotherapy in urinary bladder cancer.
The mapping of transcriptomes in individual cells from cisplatin-treated cancers was enabled by the SciLifeLab Eukaryotic Single Cell Genomics facility, providing valuable insights into chemo sensitivity and drug resistance in cancers. The researchers also used the SciLifeLab National Genomics Infrastructure and National Bioinformatics Infrastructure.
Read the full paper in Cancer Medicine
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.